Born in 1957.

Appointed in 2012, businesss developer Lars brings 35 years of experience in the pharmaceutical industry. He has been responsible for numerous negotiations with a total value of several hundred million dollars. Since 2012, he has provided consulting services in the field of business development to Lipigon.

Other positions: Chairman of the Board at Kubera Pharmaceuticals AB, Betulaceae Pharmaceuticals AB, and board member of Kubator Therapeutics AB, Cordator Life Science AB, and Immunscape AB.

Direct and/or indirect shareholdings: 343,200 shares.

Direct and/or indirect holdings of warrants: 171,600 units TO3.

Independent in relation to major shareholders but not independent in relation to the company.

Born in 1970.

Johannes assumed office in 2020. He is a physician, associate professor in cardiovascular prevention, and economist at the University of Gothenburg. As CEO of Antaros Medical.

Other positions: Chairman of the Board at Antaros Renostic AB and board member of Antaros Medical AB, Metynex Pharmaceuticals AB, Antaros Holding AB, and Guard Therapeutics International AB.

Direct and/or indirect shareholdings: 199,998 shares.

Direct and/or indirect holdings of warrants: 20,700 units 2021/2024.

Independent in relation to major shareholders but not independent in relation to the company.

Born in 1972.

Appointed in 2021, Jessica Martinsson is a pharmaceutical chemist and entrepreneur with over 25 years of experience in the pharmaceutical industry. Her career includes industrial drug development roles at Pharmacia and Biovitrum, as well as expertise in various therapy areas, including metabolic syndrome, inflammation, and cancer. She is a co-founder and COO of Sprint Bioscience, which successfully enters into significant licensing agreements for preclinical drug development in oncology.

Other positions: CEO of SwedenBio and Board member of Fragment Finans AB, a fully-owned subsidiary of Sprint Bioscience AB.

Direct and/or indirect shareholdings: 165,000 shares.

Direct and/or indirect holdings of warrants: 33,000 units TO3.

Independent in relation to the company and major shareholders

Born in 1963.

Eva assumed office in 2022. She holds a bachelor's degree in economics from Lund University. Eva brings extensive experience in developing research companies into successful pharmaceutical companies. Her previous roles include CFO positions at Camurus AB and EQL Pharma AB, as well as the role of Nordic Market Analyzer for Nordic Drugs AB.

Other roles: No other roles.

Direct and/or indirect shareholdings: 750,000 shares.

Direct and/or indirect holdings of warrants: 150,000 units TO3.

Independent in relation to the company and major shareholders.

Born in 1960.

Appointed in 2023, David Westberg holds a Master of Science in Chemical Engineering from KTH Royal Institute of Technology. He has extensive experience in drug development across various indication areas and has held prominent positions at Pharmacia Upjohn and Orexo. Since 2015, David has served as the CEO of Nanexa, a company listed on Nasdaq First North, specializing in developing new formulations of existing drugs using proprietary technology.

Other roles: No other roles.

Direct and/or indirect shareholdings: 30,000 shares.

Direct and/or indirect holdings of warrants: 0.

Independent in relation to the company and major shareholders

Born in 1971.

Appointed in 2024. Fredrik holds a law degree from Lund University and an eMBA from the Stockholm School of Business. Fredrik currently works as a board member of Magbaleo AB and Sandlund Hossain AB.

Direct and/or indirect shareholdings: 4 500 000 shares.

Direct and/or indirect holdings of warrants: 900 000 TO3.

Not independent in relation to major shareholders but independent in relation to the company.